World AIDS Day 2020, Ending the HIV/AIDS Epidemic: Resilience and Impact
Learn more about self-testing for HIV.
See if you qualify for Ready, Set, PrEP.
Learn more about the importance of viral supression.
Next week, members of the HIV community from around the globe will gather in Amsterdam for the 22nd International AIDS Conference (AIDS 2018) and HIV.gov will be there to share highlights.
More than 15,000 people—scientists, public health experts, policy makers, and members of the HIV-affected community—are expected to participate in the conference, which opens on Monday, July 23 and continues through Friday, July 27, 2018. Over 500 sessions, workshops, and program activities are planned, focusing on all facets of advancing our collective efforts to treat and prevent HIV.
The International AIDS Society, which organizes the biennial conference, has announced that among the science highlights to be showcased are important advances in HIV prevention science, including the latest research on vaccines and other future prevention tools; new lessons learned from the scale up of pre-exposure prophylaxis (PrEP); and innovative strategies for key populations, such as adolescents and young adults.
Other highlights of the research program will include:
In addition, representatives from hundreds of HIV programs will network in the Global Village, showcasing how science translates into community action and intervention. Several well-known individuals who are actively engaged in the response to HIV are also scheduled to participate in the conference, including Prince Harry and Oscar-winning actress Charlize Theron.
Throughout the week, HIV.gov will help you stay abreast of some of the news and share highlights from the conference.
You can also follow AIDS 2018 via the conference's official social media presences and website:
In preparation for the conference, visit the PEPFAR and the Global HIV epidemic pages on HIV.gov, including highlights of the U.S. Government's global HIV activities. You may also be interested in reviewing some of our recent coverage of HIV research, information about federal agencies' research activities, and basic information about potential future HIV prevention options such as a vaccine and long-acting PrEP that may be discussed during the conference.